A950130 Share Price Performance
₩5,270.00
-1820.00 (-25.67%)
Price ₩5,270.00
Share Price₩5,270.00
A950130 Community Narratives
There are no narratives available yet.
Recent A950130 News & Updates
No updates
Access Bio, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -274.01
- Gross Margin
- 41.14%
- Net Profit Margin
- -9.73%
- Debt/Equity Ratio
- 2.3%
Access Bio, Inc. Competitors
About A950130
- Founded
- 2002
- Employees
- n/a
- CEO
- WebsiteView website
Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities with limited resources; analyzers, designed to measure different chemicals and other characteristics in biological samples; and molecular diagnostic solutions used in analyzing biological markers in the genome and proteome. It offers its products under CareStart, CareUS, CareSURE, and CareGENE brand names. The company was incorporated in 2002 and is headquartered in Somerset, New Jersey.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 12.3%
- 1 Year: 21.3%
- Year to Date: 7.0%
Over the past 7 days, the market has dropped 1.2% with the Consumer Discretionary sector contributing the most to the decline. In contrast to the last week, the market is actually up 21% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading